Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >
"Positive clinical data will make CTH's APL-130277 a very attractive asset for specialty pharma or large pharma." (3/19/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Stephen Ireland More >
Companies Commented On
- Athersys Inc.
- Biotie Therapies Corp.
- Cleveland BioLabs
- Forest Laboratories Inc.
- H. Lundbeck A/S
- Intercept Pharmaceuticals Inc.
- Ironwood Pharmaceuticals Inc.
- Kyowa Hakko Kirin Co. Ltd.
- MAST Therapeutics Inc.
- Medigene AG
- Merck & Co. Inc.
- NovaBay Pharmaceuticals Inc.
- Novartis AG
- Pfizer Inc.
- Sucampo Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- UCB S.A.
Christian Glennie joined the healthcare team at Edison Investment Research in January 2012 and has 11 years' experience covering the global biotech/pharmaceutical sector as an analyst and a journalist. He came to Edison having held senior analyst and editorial roles at EvaluatePharma and EP Vantage. Christian Glennie also has prior experience as a marketing analyst at Zeneca Agrochemicals.
Seven Biotech Options that Buck Tradition: Christian Glennie (6/6/13) Edison Investment Research assesses the value of emerging companies with a model that assumes revenues and earnings are years away. Then again, every investor does that. What's unusual is that Edison looks for tomorrow's upside in companies still small enough to double, triple and quadruple in value down the line. In this interview with The Life Sciences Report, Edison Biotechnology Analyst Christian Glennie applies his valuation skills to seven innovative biotech and specialty pharma companies and discusses the share-moving catalysts that investors need to know about now.
"A $2.8M research grant enables ATHX's MultiStem to enter a third phase 2 trial to evaluate the safety and therapeutic impact of its allogeneic adult stem cells." (8/9/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >
"If the data from the PRESERVE trial are positive, NEO may be able to enter partnership in the regenerative medicine space." (4/22/14) NeoStem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju More >